David Duhamel, MD
Critical Care Medicine · Arlington, VANPI 1609869932
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Boston Scientific at 29.9% of the total. Reporting peaked in 2019 at $7,819 and has fallen 63.0% since, to $2,890 in 2025. Among critical care medicine clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 73 payments — averaging $240.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$5K
- Cook Incorporated$4K
- Pulmonx Corporation$3K
- Medical Device Business Services, Inc.$2K
- Noah Medical Corporation$1K
- AstraZeneca$349
- plus $1K from 21 others
Across 1 payment — averaging $450.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$451
What the payments were for
- Consulting fees$7,67544%
- Speaking & faculty fees$4,40025%
- Travel & lodging$2,54815%
- Food & beverage$2,94917%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 10 | $5,262 |
| Cook Incorporated | 1 | $4,400 |
| Pulmonx Corporation | 2 | $3,050 |
| Medical Device Business Services, Inc. | 8 | $2,422 |
| Noah Medical Corporation | 2 | $1,055 |
| AstraZeneca | 7 | $349 |
| GSK | 14 | $310 |
| Genentech USA, Inc. | 1 | $125 |
| Sanofi | 5 | $111 |
| Shionogi Inc | 3 | $84 |
| United Therapeutics Corporation | 2 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Cook Medical LLC | 2 | $37 |
| Insmed, Inc. | 1 | $27 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Pinnacle Biologics, Inc | 1 | $23 |
| Grifols USA, LLC | 1 | $22 |
| Mylan Specialty L.p. | 1 | $20 |
| Viatris Specialty LLC | 1 | $20 |
| Bard Access Systems, Inc. | 1 | $19 |
| Electromed, Inc. | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| Covidien LP | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Galderma Laboratories, L.p. | 1 | $13 |
| Ambu Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL PULMONARY$5,001
- Cook Medical Percutaneous Tracheostomy$4,400
- Pulmonx Endobronchial Valve EBV$3,000
- MONARCH$2,422
- BREZTRI$251
- Esbriet$125
- NUCALA$124
How this compares
$17,572 in reported general payments places this provider in the 90th percentile of 174 critical care medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 214 | $333,455 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 40 | $69,277 |
| Breo ElliptaFluticasone/Vilanterol | 57 | $40,532 |
| Spiriva RespimatTiotropium Bromide | 16 | $24,947 |
| EliquisApixaban | 18 | $23,786 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 20 | $22,295 |
| Spiriva HandihalerTiotropium Bromide | 13 | $9,361 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 32 | $7,476 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $7,354 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 11 | $4,767 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $2,995 |
| Wixela InhubFluticasone Propion/Salmeterol | 21 | $2,902 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 90 | $2,620 |
| Ventolin HfaAlbuterol Sulfate | 21 | $1,661 |
| Montelukast Sodium | 79 | $1,191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $310 | $373,987271 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $349 | $81,39863 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 174 critical care medicine providers in Virginia.
Other critical care medicine in Arlington
- Jeff HalesArlington$37K
- Oksana ShlobinFalls Church$375K
- Matthew WilliamsAnnandale$235K
- Sami Abdul JawadFalls Church$193K
- Rajiv MalhotraRichmond$187K
- Thomas BouderWinchester$163K
- Christopher KingFalls Church$131K
- Rohit GoyalFredericksburg$95K
- Robert ThieleCharlottesville$52K
- Paul MarikNorfolk$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.